Abstract

BackgroundManagement of locally recurrent rectal cancer (LRRC) after surgery or external beam radiotherapy (EBRT) remains a clinical challenge, given the limited treatment options and unsatisfactory outcomes. This study aimed to assess long-term outcomes of computed tomography (CT)-guided radioactive 125I seed implantation in patients with LRRC and associated prognostic factors.MethodsA total of 101 patients with LRRC treated with CT-guided 125I seed implantation from October 2003 to April 2019 were retrospectively studied. Treatment procedures involved preoperative planning design, 125I seed implantation, and postoperative dose evaluation. We evaluated the therapeutic efficacy, adverse effects, local control (LC) time, and overall survival (OS) time.ResultsAll the patients had previously undergone surgery or EBRT. The median age of patients was 59 (range, 31–81) years old. The median follow-up time was 20.5 (range, 0.89–125.8) months. The median LC and OS time were 10 (95% confidence interval (CI): 8.5–11.5) and 20.8 (95% CI: 18.7–22.9) months, respectively. The 1-, 2-, and 5-year LC rates were 44.2%, 20.7%, and 18.4%, respectively. The 1-, 2-, and 5-year OS rates were 73%, 31.4%, and 5%, respectively. Univariate analysis of LC suggested that when short-time tumor response achieved partial response (PR) or complete response (CR), or D90>129 Gy, or GTV ≤ 50 cm3, the LC significantly prolonged (P=0.044, 0.041, and <0.001, respectively). The multivariate analysis of LC indicated that the short-time tumor response was an independent factor influencing LC time (P<0.001). Besides, 8.9% (9/101) of the patients had adverse effects (≥grade 3): radiation-induced skin reaction (4/101), radiation-induced urinary reaction (1/101), fistula (2/101), and intestinal obstruction (2/101). The cumulative irradiation dose and the activity of a single seed were significantly correlated with adverse effects ≥grade 3 (P=0.047 and 0.035, respectively).ConclusionCT-guided 125I seed implantation is a safe and effective salvage treatment for LRRC patients who previously underwent EBRT or surgery. D90 and GTV significantly influenced prognosis of such patients.

Highlights

  • Recurrent rectal cancer (LRRC) refers to the recurrence, progression, or development of new sites within the pelvis after previous standard treatment for rectal cancer [1]

  • No correlation was found between D90 (D90 ≤ 129 Gy vs. D90>129 Gy) and adverse effects ≥grade 3 (P=0.160) (Table 2)

  • Numerous therapeutic modalities have been used for patients with Locally recurrent rectal cancer (LRRC), including surgery, external beam radiotherapy (EBRT), intraoperative radiotherapy (IORT), high-dose-rate (HDR) brachytherapy, chemotherapy, etc

Read more

Summary

Introduction

Recurrent rectal cancer (LRRC) refers to the recurrence, progression, or development of new sites within the pelvis after previous standard treatment for rectal cancer [1]. Because the tumor typically shows extensive involvement in the pelvis, less than one-sixth of patients are eligible for R0 resection [5]. The benefits of reirradiation include possible palliation by decreased steroid use, improvement in neurological symptoms, and extension of progression-free survival (PFS) and overall survival (OS) in some patients. Locally recurrent tumors are mostly located in the previously irradiated field, making it more challengeable for patients to undergo reirradiation [7]. Management of locally recurrent rectal cancer (LRRC) after surgery or external beam radiotherapy (EBRT) remains a clinical challenge, given the limited treatment options and unsatisfactory outcomes. This study aimed to assess long-term outcomes of computed tomography (CT)-guided radioactive 125I seed implantation in patients with LRRC and associated prognostic factors. We evaluated the therapeutic efficacy, adverse effects, local control (LC) time, and overall survival (OS) time

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call